Michael Barbella, Managing Editor04.02.24
In partnership with GS2, the U.S. Department of Veterans Affairs (VA) has awarded a contract to Linear Health Sciences for its Orchid SRV tension-activated breakaway safety release valve.
The Orchid SRV is a sterile, single-use connector for needle-free access that makes return to treatment fast, simple, and clean, according to the company. Clinical simulation testing of 360 Orchid SRVs showed the device prevented IV dislodgement by 91.9% across all test groups. The device is placed between an existing IV extension set and general IV tubing connection that delivers fluids to and from an IV catheter.
“This contract allows the VA system to evaluate and adopt the Orchid SRV in a patient population that can directly benefit from its function,” Linear Health Sciences Co-Founder/CEO Dan Clark said. “It’s a significant step toward providing our veterans with the level of care they deserve.”
According to a study published in J-AVA, 95% of 1,561 U.S. clinicians surveyed agreed that IV dislodgement continues to pose safety risks for patients and hospitals. Of the 342 million peripheral IVs deployed each year in the U.S.,1 up to 10% may dislodge,2 costing more than $2 billion annually.3 Dislodgement is most frequently caused by patient confusion or removal of the catheter, loose dressing or tape, or tubing becoming tangled in bed linens.
“This device is innovative, saves hospitals money, and increases customer service and quality of care for all patients who need an IV. Veterans deserve the best technology offered on the market today. The Orchid should be in stock at every VA hospital,” GS2 Global CEO Blaine Hedges stated.
The Orchid SRV has also received an Innovative Technology contract from Vizient Inc., the nation’s largest member-driven healthcare performance improvement company, and was awarded a national group purchasing agreement for the IV Therapy - Needleless Connectors category with Premier Inc.
Linear Health Sciences has developed a proprietary, breakaway safety valve technology designed to improve hospitals' medical tubing use. The platform technology was developed to increase the safety and satisfaction of patients, caregivers, and healthcare facilities, while dramatically reducing costs. The company’s initial products include the Orchid SRV for use in IV catheter therapy and the Orchid SRV Type D device for use in surgical/wound, nephrostomy and abscess drainage.
References
1 iData research report
2 "The Peripheral Intravenous Catheter Journey: A Prospective Cohort Study of 1000 Patients." Podium presentation
3 Helm, et al. “Accepted but unacceptable: peripheral IV catheter failure” J Infus Nurs May-Jun 2015;38(3):189-203. doi: 10.1097/NAN.0000000000000100
The Orchid SRV is a sterile, single-use connector for needle-free access that makes return to treatment fast, simple, and clean, according to the company. Clinical simulation testing of 360 Orchid SRVs showed the device prevented IV dislodgement by 91.9% across all test groups. The device is placed between an existing IV extension set and general IV tubing connection that delivers fluids to and from an IV catheter.
“This contract allows the VA system to evaluate and adopt the Orchid SRV in a patient population that can directly benefit from its function,” Linear Health Sciences Co-Founder/CEO Dan Clark said. “It’s a significant step toward providing our veterans with the level of care they deserve.”
According to a study published in J-AVA, 95% of 1,561 U.S. clinicians surveyed agreed that IV dislodgement continues to pose safety risks for patients and hospitals. Of the 342 million peripheral IVs deployed each year in the U.S.,1 up to 10% may dislodge,2 costing more than $2 billion annually.3 Dislodgement is most frequently caused by patient confusion or removal of the catheter, loose dressing or tape, or tubing becoming tangled in bed linens.
“This device is innovative, saves hospitals money, and increases customer service and quality of care for all patients who need an IV. Veterans deserve the best technology offered on the market today. The Orchid should be in stock at every VA hospital,” GS2 Global CEO Blaine Hedges stated.
The Orchid SRV has also received an Innovative Technology contract from Vizient Inc., the nation’s largest member-driven healthcare performance improvement company, and was awarded a national group purchasing agreement for the IV Therapy - Needleless Connectors category with Premier Inc.
Linear Health Sciences has developed a proprietary, breakaway safety valve technology designed to improve hospitals' medical tubing use. The platform technology was developed to increase the safety and satisfaction of patients, caregivers, and healthcare facilities, while dramatically reducing costs. The company’s initial products include the Orchid SRV for use in IV catheter therapy and the Orchid SRV Type D device for use in surgical/wound, nephrostomy and abscess drainage.
References
1 iData research report
2 "The Peripheral Intravenous Catheter Journey: A Prospective Cohort Study of 1000 Patients." Podium presentation
3 Helm, et al. “Accepted but unacceptable: peripheral IV catheter failure” J Infus Nurs May-Jun 2015;38(3):189-203. doi: 10.1097/NAN.0000000000000100